- The FDA approves Dr. Reddy's Laboratories' (NYSE:RDY) drug-device combination product, ZEMBRACESymTouch (sumatriptan succinate) injection, for the treatment of acute migraine episodes, with or without aura, in adults who are inadequately managed with existing regimens. The product is a prefilled, ready-to-use, single-dose disposable autoinjector containing 3 mg of sumatriptan, the most commonly prescribed medication for migraine.
- ZEMBRACESymTouch will be marketed in the U.S. by Promius Pharma, a wholly owned specialty company of Dr. Reddy's.